Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in Valencia – page 14

1 777 clinical trials in Valencia, Spain across 8 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Valencia at a glance
1 777
clinical trials
  • Research sites8
Type of trial
Recruitment status
Quick filters

1 777 trials in Valencia

Open in trial search

Acute myeloid leukaemia refractory+2

Recruiting

Phase 1/2 Study of LB-208 in Adults with Relapsed or Refractory Acute Myeloid Leukaemia and High‑Risk Myelodysplastic Syndrome

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Sponsor:Aop Orphan Pharmaceuticals GmbH

Rett syndrome

Recruiting

A Phase 3 Study of Fenfluramine Hydrochloride for Safety and Efficacy in Patients with Rett Syndrome

Registered drug
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years
  • Substances:Fenfluramine Hydrochloride
  • Sponsor:UCB Biosciences Inc.

Non-small cell lung cancer metastatic

Recruiting

Phase 2 Study of Rinatabart Sesutecan with PEGFILGRASTIM in Adults with Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:HUMAN IGG1 KAPPA MONOCLONAL ANTIBODY AGAINST FOLR1 CONJUGATED TO 1-[(2R,3R,4R,5S,52S)-1,2,3,4,5-PENTAHYDROXY-52-{[(2S)-1-{[(2S)-5-CARBAMOYLAMINO-1-OXO-1-{3-[({[(1S,9S)-9-ETHYL-5-FLUORO-9-HYDROXY-4-METHYL10,13-DIOXO-2,3,9,10,13,15-HEXAHYDRO-1H,12HBENZO[DE]PYRANO[3',4':6,7]INDOLIZINO[1,2-B]QUINOLIN-1-YL]CARBAMOYL}OXY)METHYL]ANILINO}PENTAN-2-YL]AMINO}-3-METHYL-1-OXOBUTAN-2-YL]CARBAMOYL}-7-[(2S,3R,4R,5R)-2,3,4,5,6-PENTAHYDROXYHEXYL]-46,54-DIOXO10,13,16,19,22,25,28,31,34,37,40,43-DODECAOXA-7,47,53-TRIAZANONAPENTACONTAN-59-YL]-2,5-DIOXOPYRROLIDIN-3-YL
  • Sponsor:Genmab A/S

Squamous cell carcinoma of lung+4

Recruiting

A study of PF-08634404 and sigvotatug vedotin in patients with advanced solid tumors

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:SIGVOTATUG VEDOTIN
  • Sponsor:Pfizer Inc.

Obesity+2

Recruiting

A study to evaluate the effects of zenagamtide on weight and pain in patients with overweight or obesity and knee osteoarthritis

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Sponsor:Novo Nordisk A/S

Obesity+2

Recruiting

A study to evaluate the efficacy and safety of zenagamtide in people with overweight or obesity and knee osteoarthritis

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Sponsor:Novo Nordisk A/S

Juvenile idiopathic arthritis

Recruiting

A study to evaluate the safety and effectiveness of filgotinib in children and adolescents aged 8 to 17 years with polyarticular juvenile idiopathic arthritis

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years
  • Substances:Filgotinib
  • Sponsor:Alfasigma S.p.A.

Acute lymphocytic leukaemia

Recruiting

Study of Blinatumomab and a drug combination for older adults with newly diagnosed Philadelphia-negative B-cell precursor Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Asparaginase
  • Sponsor:Amgen Inc.

Amyotrophic lateral sclerosis

Recruiting

A study to evaluate the safety of VTx-002 in patients with amyotrophic lateral sclerosis.

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:VTX-002
  • Sponsor:VectorY Therapeutics B.V.

Non-small cell lung cancer

Recruiting

Comparing Sotorasib and Pembrolizumab with chemotherapy for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Amgen Inc.

Ovarian epithelial cancer

Recruiting

Comparing AZD5335 with Mirvetuximab Soravtansine or a drug combination in patients with platinum-resistant ovarian cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:AZD5335
  • Sponsor:AstraZeneca AB

Endometrial cancer+2

Recruiting

A study comparing Rinatabart Sesutecan to other treatments in patients with endometrial cancer who have previously received platinum-based chemotherapy and PD-L1 therapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Paclitaxel
  • Sponsor:Genmab A/S

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Valencia

What the registry says about research in the country

01 Oncology & Hematology

Innovative research focused on Mantle Cell Lymphoma treatments and Immune Thrombocytopenia, evaluating novel therapeutic combinations and investigating new treatment approaches.

  • Lymphoma therapies
  • Blood disorders
  • Immunotherapy combinations

Studies aim to improve treatment outcomes and provide alternative therapeutic options for patients.

02 Respiratory Medicine

Comprehensive studies addressing Respiratory Syncytial Virus, ARDS, and COPD, with focus on innovative treatments and preventive measures.

  • Viral respiratory infections
  • Acute respiratory conditions
  • Vaccine development

Research emphasizes both therapeutic interventions and preventive strategies for respiratory diseases.

03 Neurology & Stroke

Advanced research into acute ischemic stroke treatments and outcomes, investigating novel therapeutic approaches for better patient recovery.

  • Stroke treatment
  • Neurological recovery
  • Reperfusion therapies

Focus on improving functional outcomes and reducing complications in stroke patients.

Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.